227 related articles for article (PubMed ID: 19362126)
21. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid.
Dautry C; Vaufrey F; Brouillet E; Bizat N; Henry PG; Condé F; Bloch G; Hantraye P
J Cereb Blood Flow Metab; 2000 May; 20(5):789-99. PubMed ID: 10826529
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms underlying striatal vulnerability to 3-nitropropionic acid.
Herrera-Mundo N; Sitges M
J Neurochem; 2010 Jul; 114(2):597-605. PubMed ID: 20477912
[TBL] [Abstract][Full Text] [Related]
23. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo.
Yang L; Sugama S; Mischak RP; Kiaei M; Bizat N; Brouillet E; Joh TH; Beal MF
Neurobiol Dis; 2004 Nov; 17(2):250-9. PubMed ID: 15474362
[TBL] [Abstract][Full Text] [Related]
24. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
25. Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid.
Blum D; Hemming FJ; Galas MC; Torch S; Cuvelier L; Schiffmann SN; Sadoul R
Neurosci Lett; 2004 Sep; 368(3):309-13. PubMed ID: 15364417
[TBL] [Abstract][Full Text] [Related]
26. Extracting the basal extracellular dopamine concentrations from the evoked responses: re-analysis of the dopamine kinetics.
Chen KC; Budygin EA
J Neurosci Methods; 2007 Aug; 164(1):27-42. PubMed ID: 17498808
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
28. Nigral injection of antisense oligonucleotides to synaptotagmin I using HVJ-liposome vectors causes disruption of dopamine release in the striatum and impaired skill learning.
Akita H; Ogata M; Jitsuki S; Ogura T; Oh-Nishi A; Hoka S; Saji M
Brain Res; 2006 Jun; 1095(1):178-89. PubMed ID: 16729982
[TBL] [Abstract][Full Text] [Related]
29. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
Dalbem A; Silveira CV; Pedroso MF; Breda RV; Werne Baes CV; Bartmann AP; da Costa JC
Brain Res; 2005 Jun; 1047(2):148-58. PubMed ID: 15901483
[TBL] [Abstract][Full Text] [Related]
30. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
Pérez-De La Cruz V; Elinos-Calderón D; Robledo-Arratia Y; Medina-Campos ON; Pedraza-Chaverrí J; Ali SF; Santamaría A
Behav Brain Res; 2009 May; 199(2):210-7. PubMed ID: 19100293
[TBL] [Abstract][Full Text] [Related]
31. Motor function and dopamine release measurements in transgenic Huntington's disease model rats.
Ortiz AN; Osterhaus GL; Lauderdale K; Mahoney L; Fowler SC; von Hörsten S; Riess O; Johnson MA
Brain Res; 2012 Apr; 1450():148-56. PubMed ID: 22418060
[TBL] [Abstract][Full Text] [Related]
32. 17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
Túnez I; Collado JA; Medina FJ; Peña J; Del C Muñoz M; Jimena I; Franco F; Rueda I; Feijóo M; Muntané J; Montilla P
Neurochem Int; 2006 Apr; 48(5):367-73. PubMed ID: 16420966
[TBL] [Abstract][Full Text] [Related]
33. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
Johnson MA; Rajan V; Miller CE; Wightman RM
J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064
[TBL] [Abstract][Full Text] [Related]
35. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
de Lago E; Urbani P; Ramos JA; Di Marzo V; Fernández-Ruiz J
Brain Res; 2005 Jul; 1050(1-2):210-6. PubMed ID: 15975564
[TBL] [Abstract][Full Text] [Related]
36. Controlled cortical impact injury affects dopaminergic transmission in the rat striatum.
Wagner AK; Sokoloski JE; Ren D; Chen X; Khan AS; Zafonte RD; Michael AC; Dixon CE
J Neurochem; 2005 Oct; 95(2):457-65. PubMed ID: 16190869
[TBL] [Abstract][Full Text] [Related]
37. Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with Carboplatin.
Kaplan SV; Limbocker RA; Gehringer RC; Divis JL; Osterhaus GL; Newby MD; Sofis MJ; Jarmolowicz DP; Newman BD; Mathews TA; Johnson MA
ACS Chem Neurosci; 2016 Jun; 7(6):689-99. PubMed ID: 27145395
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine.
Nishimura M; Okimura Y; Fujita H; Yano H; Lee J; Suzaki E; Inoue M; Utsumi K; Sasaki J
Cell Biochem Funct; 2008 Dec; 26(8):881-91. PubMed ID: 18942062
[TBL] [Abstract][Full Text] [Related]
39. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat.
Blum D; Gall D; Cuvelier L; Schiffmann SN
Neuroreport; 2001 Jun; 12(8):1769-72. PubMed ID: 11409756
[TBL] [Abstract][Full Text] [Related]
40. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
Neurosci Lett; 2011 Mar; 492(1):11-4. PubMed ID: 21256185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
